Clinical trials: completed, sponsored by Bristol-Myers Squibb
HIV Infections
Effectiveness and Safety of Two Forms of Stavudine in HIV-Infected Patients
The purpose of this study is to compare the safety and effectiveness of 2 forms of stavudine (d4T). One form is taken once a day (extended release) and the other form is taken twice a day (immediate release).
- Trial name
- NCT00005918
- Testing
- Efavirenz, Lamivudine, Stavudine
- Where
- 77 sites in United States, Argentina and 14 more
- Volunteers
- 730 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Study of a New Protease Inhibitor, BMS-232632, in Combination With Other Anti-HIV Drugs
The purpose of this study is to evaluate a new protease inhibitor known as BMS-232632. This drug will be given in combination with 2 other anti-HIV drugs (stavudine and didanosine).
- Trial name
- NCT00002240
- Testing
- Atazanavir, Nelfinavir mesylate, Stavudine
- Where
- 17 sites in United States, Canada
- Sponsor
- Bristol-Myers Squibb
Leukemia
Chronic Myelogenous Leukemia or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemic Study
To determine the long term safety and tolerability of dasatinib exposure in subjects previously treated in CA180-002.
- Trial name
- NCT00978731
- Testing
- Dasatinib
- Volunteers
- 46 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections, AIDS
DART II - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of stavudine extended release (d4T XR), lamivudine (3TC), and efavirenz (EFV) leads to improved outcomes, as measured by viral load, CD4…
- Trial name
- NCT00116116
- Testing
- efavirenz, stavudine extended release, lamivudine
- Where
- 10 sites in United States
- Volunteers
- 70 people
- Sponsor
- Bristol-Myers Squibb
Breast Cancer, Metastasis
Study of Dasatinib (BMS-354825) in Patients With Advanced Estrogen/Progesterone Receptor-positive (ER+/PR+) or Her2/Neu-positive (Her2/Neu+)Breast Cancer
This study will determine whether the investigational drug dasatinib is effective in treatment of women with progressive advanced ER+/PR+ or Her2/neu+ breast cancer
- Trial name
- NCT00371345
- Testing
- Dasatinib, Dasatinib 100 mg
- Where
- 23 sites in United States, Argentina and 5 more
- Volunteers
- 92 people
- Sponsor
- Bristol-Myers Squibb
Head and Neck Cancer
Early Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Advanced or Recurrent Head and Neck Cancer
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent head and neck cancer
- Trial name
- NCT01024101
- Testing
- Paclitaxel
- Volunteers
- 36 people
- Sponsor
- Bristol-Myers Squibb
Non-Small Cell Lung Cancer
Phase II Study of Weekly Paclitaxel (BMS-181339) in Patient With Non-Small Cell Lung Cancer (NSCLC)
The purpose of this study is to evaluate the efficacy and the safety of paclitaxel given weekly in patients with advanced or recurrent non-small cell lung cancer
- Trial name
- NCT01024062
- Testing
- Paclitaxel
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Switching HIV-1 Infected Subjects From a Highly Active Anti-Retroviral Treatment (HAART) Regimen Dosed Twice Daily or More Frequently to a Once-Daily Regimen
The purpose of this study is to demonstrate that virologically controlled HIV-infected individuals can successfully switch from a standard-of-care regimen dosed twice-daily or more frequently to a simpler once-daily (QD) regimen…
- Trial name
- NCT00135369
- Testing
- stavudine extended-release, lamivudine, efavirenz
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 300 people
- Sponsor
- Bristol-Myers Squibb
Hypercholesterolemia
Pravastatin Efficacy and Safety Trial in Hypercholesterolemic Patients With Chronic Liver Disease
To determine in hypercholesterolemic subjects with chronic, well-compensated liver disease, the percent change from baseline to Week 12 in serum LDL-C of pravastatin 80 mg compared to placebo.
- Trial name
- NCT00529178
- Testing
- Pravastatin
- Volunteers
- 232 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
Comparison of Two Anti-HIV Regimens That Include One of Two Forms of Didanosine (ddI)
Didanosine is an effective anti-HIV drug, but it can cause stomach upset. This study tests a new form of didanosine, ddI EC, a coated pill that passes through the stomach more easily and hopefully will prevent stomach upset.
- Trial name
- NCT00002224
- Testing
- Nelfinavir mesylate, Stavudine, Didanosine
- Where
- 24 sites in United States, Canada
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Psoriasis Vulgaris
Phase II Randomized, Double-Blind, Placebo-Controlled Study of BMS-188667 (CTLA4Ig) in Patients With Psoriasis Vulgaris
The purpose of this study is to assess the safety, pharmacokinetics and clinical activity and immunogenicity of BMS-188667 (CTLA4Ig) in subjects with psoriasis vulgaris
- Trial name
- NCT00287547
- Testing
- CTLA4Ig / Abatacept
- Where
- 10 sites in United States
- Volunteers
- 144 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections, AIDS
Rollover Study for Zerit (Stavudine) ER Studies (-096, -099)
The purpose of this study is to compare long-term safety and tolerability of stavudine (d4T) extended release (ER) versus conventional (immediate release [IR]) formulations, each in combination with lamivudine (3TC) and efavirenz…
- Trial name
- NCT00116298
- Testing
- stavudine, efavirenz, lamivudine
- Where
- 63 sites in United States, Argentina and 14 more
- Volunteers
- 900 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Comparison of Two Dose Levels of Didanosine Used in Combination With Stavudine in HIV-Infected Patients
The purpose of this study is to compare the effectiveness of taking didanosine (ddI) once a day plus stavudine (d4T) twice a day with taking ddI twice a day plus d4T twice a day.
- Trial name
- NCT00002207
- Testing
- Stavudine, Didanosine
- Where
- 13 sites in United States
- Sponsor
- Bristol-Myers Squibb
HIV Infections
A Comparison of Two Triple-Drug Combinations in Patients Who Have Never Been Treated With Anti-HIV Drugs
The purpose of this study is to compare the safety of didanosine plus stavudine plus nelfinavir (NLF) with that of zidovudine plus lamivudine plus NLF.
- Trial name
- NCT00002411
- Testing
- Nelfinavir mesylate, Lamivudine, Stavudine
- Where
- 32 sites in United States
- Sponsor
- Bristol-Myers Squibb
Rheumatoid Arthritis
A Study of Abatacept in Japanese Patients With Active Rheumatoid Arthritis While Receiving Methotrexate
The purpose of this study is to demonstrate that Abatacept combined with Methotrexate will demonstrate a dose response efficacy in Japanese subjects with active Rheumatoid Arthritis similar to the dose response efficacy…
- Trial name
- NCT00345748
- Testing
- Abatacept
- Where
- 38 sites in Japan
- Volunteers
- 194 people
- Sponsor
- Bristol-Myers Squibb
HIV Infections, AIDS
DART I - A Phase IV Study of 3 Antiretroviral Medicines in Combination, in HIV Patients Who Have Not Been Previously Treated With Antiretroviral Therapy
The purpose of this study is to evaluate whether a therapy with an all once daily regimen of efavirenz (EFV), didanosine (ddI)-EC and lamivudine (3TC) leads to improved outcomes, as measured by viral load, CD4 counts, adherence…
- Trial name
- NCT00116415
- Testing
- efavirenz; didanosine EC; lamivudine
- Where
- 9 sites in United States
- Volunteers
- 65 people
- Sponsor
- Bristol-Myers Squibb
AIDS
To Assess Compliance With a Once-daily Regimen of Lamivudine, Efavirenz and Didanosine
To assess compliance of once daily dosing to assess their benefits in terms of potency and safety as well as their impact on adherence and quality of life.
- Trial name
- NCT00207168
- Testing
- Compliance
- Volunteers
- 120 people
- Sponsor
- Bristol-Myers Squibb
Neoplasms
Phase I (PH I) Mad Refractory Solid Tumor Study
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, effect of food, and continue exploratory research of BMS-354825 in patients with solid tumors not responding to standard treatment, or for which…
- Trial name
- NCT00099606
- Testing
- Dasatinib
- Where
- 3 sites in United States, United Kingdom
- Volunteers
- 60 people
- Sponsor
- Bristol-Myers Squibb
Hepatitis B
A Phase IIIb: Long-Term Outcomes for Hepatitis B (HepB) Patients in Some Previous Entecavir (ETV) Trials
The purpose of this study is to follow patients treated in entecavir Phase III and rollover studies for safety experience and Hepatitis B virus (HBV)-related complications.
- Trial name
- NCT01337479
- Volunteers
- 1,097 people
- Sponsor
- Bristol-Myers Squibb
Actue Coronary Syndromes
Pravastatin or Atorvastatin Evaluation and Infection Therapy (TIMI22)
The primary purpose of the study was to evaluate 4000 subjects with acute coronary syndrome by comparing pravastatin 40 mg to atorvastatin 80 mg to determine if they are clinically equivalent, and to evaluate the effectiveness of…
- Trial name
- NCT00382460
- Testing
- PRAVASTATIN SODIUM
- Volunteers
- 4,000 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.